2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
生物活性
Description
In Vivo
In Vitro
化合物的使用
Kinase Assay
Cell Assay
Animal Administration
参考文献
ABT-199 is a potent and selective inhibitor of B-cell lymphoma-2 (BCL-2) family proteins, currently in clinical trials. It is an engineered version of ABT-263 (Navitoclax) but with much better selectivity. It selectively hits Bcl-2 while ABT-263 hits both Bcl-2 and Bcl-xl.
For the detailed information about the solubility of ABT-199 (GDC-0199) in water, the solubility of ABT-199 (GDC-0199) in DMSO, the solubility of ABT-199 (GDC-0199) in PBS buffer, the animal experiment（test） of ABT-199 (GDC-0199),the in vivo,in vitro and clinical trial test of ABT-199 (GDC-0199),the cell experiment（test） of ABT-199 (GDC-0199),the IC50, EC50 and Affinity of ABT-199 (GDC-0199), please contact DC Chemicals.
